Inovio Pharmaceuticals, Inc.
GBM.F
Frankfurt Stock Exchange0.96
EUR
-0.06
- -
ISIN
US45773H4092
CUSIP
45773H409
Return %
Stock
S&P500
1Y
-48.85
26.57
3Y
-85.08
76.60
5Y
-98.76
78.48
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jacqueline E. Shea
- Full Time Employees
- 134
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 660 West Germantown Pike Plymouth Meeting PA United States of America 19462
- IPO Date
- Apr 7, 2005
- Website
- inovio.com
- Similar Companies
- Business
- Inovio Pharmaceuticals, Inc. manufactures and develops DNA medicines for cancer, infectious diseases, and HPV-associated conditions; it also provides delivery platforms and related clinical development services. The company focuses on therapeutic vaccines and DNA-based immunotherapies using its SynCon DNA sequence design platform and CELLECTRA delivery devices to enhance uptake and immune response. Main products and services: - DNA medicines portfolio: therapeutic vaccines for HPV-related diseases (cervical, vulvar, anal dysplasia and cancers), glioblastoma and other cancers, infectious disease targets (HIV, Ebola, MERS, Lassa fever), and potential programs in other oncologic and viral indications. - SynCon DNA design technology: computational optimization of target antigens to elicit robust immune responses. - CELLECTRA delivery platform: minimally invasive, intradermal or intramuscular delivery systems that improve plasmid uptake and expression. - Clinical development services and protocols: design and execution of Phase I–III oncology and infectious disease trials in collaboration with partners. Latest major company changes: - Strategic focus shifts toward advancing late-stage programs and exploring combination therapies with partners in oncology and infectious disease spaces; recent steps include advancing INO-3107 for recurrent respiratory papillomatosis (RRP) and pursuing further HPV-related program development, with emphasis on Phase 2/3 progression where applicable. - Partnerships and collaborations: ongoing alliances with biotechnology and pharmaceutical partners to co-develop and co-fund clinical programs and to leverage external expertise in regulatory strategy and commercialization. - Product launches and pipeline expansion: continued advancement of DNA medicines pipeline with candidate updates and trial initiations for HPV-related precancers and related cancers, alongside exploration of multi-antigen approaches and combination regimens. - Corporate and operational changes: organization aligns around bolstering late-stage clinical execution and regulatory readiness; potential refinements to manufacturing and supply chain to support expanded clinical activity. Additional context: - Industry and segments: biotechnology; therapeutic vaccines and immunotherapies; oncology and infectious disease. - Target markets and customer types: healthcare providers, academic medical centers, contract research organizations, and potential licensing or commercialization partners. - Geographic operations: global footprint with development activities and trials conducted in multiple regions; headquarters in the United States, with international collaborators and sites for studies. - Founding year and headquarters: founded in 1999; headquartered in the United States (specific address not disclosed here). - Subsidiaries and parent relationships: operates as an independent publicly traded biotechnology company with development programs that may involve collaboration with partners and potential subsidiary structures or contractual affiliates as part of joint development agreements. Notes: - Inovio’s core value proposition lies in its DNA medicines platform, aimed at producing targeted immune responses against HPV-associated diseases, certain cancers, and select infectious diseases, supported by its SynCon design and CELLECTRA delivery technology.